首页> 中文期刊> 《中国医药指南》 >强化阿托伐他汀治疗对急性冠状动脉综合征患者心功能的影响

强化阿托伐他汀治疗对急性冠状动脉综合征患者心功能的影响

         

摘要

目的:探讨强化阿托伐他汀治疗对急性冠状动脉综合征(ACS)患者心功能的影响。方法选择2012年1月至2012年12月在我院心内科住院确诊的ACS患者160例,将患者随机分为2组。分别为阿托伐他汀(辉瑞)20 mg/d常规治疗组及首剂80 mg负荷量,继之40 mg/d强化治疗组。所有实验对象在研究初始及2周后2次行肝功能、肌酸激酶、肾功能、血浆同型半胱氨酸(Hcy)、一氧化氮(nitric oxide,NO)浓度、血浆脑利钠肽(BNP)浓度测定。结果与常规治疗组比较,阿托伐他汀强化治疗组血浆Hcy、BNP水平明显降低,差异有统计学意义;两组治疗后NO水平明显升高,以强化治疗组升高更为显著,差异有统计学意义;无肝肾功能损伤、肌酸激酶明显升高等不良反应。结论对ACS患者来说,与20 mg/d阿托伐他汀比较,强化阿托伐他汀治疗可降低血浆同型半胱氨酸水平、改善患者心功能。%Objective To observe the effects of atorvastatin loading on cardiac function in patients with acute coronary syndyome (ACS). Methods Totally 160 patients with ACS in The iffth afifliated hospital of Zhengzhou University Cardiology from January 2012 to December 2012 were randomly divided into treatment group and control group. Treatment group were given a 80 mg loading dose, then atorvastatin 40 mg/d, control group were given atorvastatin 20 mg/d. Liver function, levels of serum creatine kinase (CK), renal function, plasma homocysteine (Hcy), nitric oxide (NO) and plasma brain natriuretic peptide (BNP) were measured before treatment and two weeks later. Results Levels of plasma Hcy and BNP in treatment group were signiifcantly lower than those in control group, the difference was statistically signiifcant;NO levels of the two groups improved signiifcantly, and treatment group increased more signiifcantly, the difference was statistically signiifcant;No liver and renal function damage, signiifcantly increased levels of serum CK were observed. Conclusions Atorvastatin loading given can reduce levels of plasma Hcy, improve ACS patients’ cardiac function.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号